-
Views
-
Cite
Cite
Sumeska Thavarajah, George A Mansoor, Beatriz E Tendler, William B White, P-600: Primary aldosteronism with and without hypertensive urgency : Clinical and biochemical features: , American Journal of Hypertension, Volume 16, Issue S1, May 2003, Page 256A, https://doi.org/10.1016/S0895-7061(03)00773-8
- Share Icon Share
Abstract
is commonly considered in the diagnosis of a patient with hypokalemia or difficult to control hypertension. Clinical manifestations of PA are highly variable and serious hypertensive urgencies and emergencies are said to be rare. We performed a retrospective analysis of patients diagnosed with PA to identify clinical or biochemical features that would be predictive of a hypertensive emergency or urgency. Fifty-three patients who were evaluated from 1996 through 2002 at the University of Connecticut Health Center were included in this analysis. Patients included had a confirmed diagnosis of PA including a sodium suppression study and appropriate anatomic localization. They were classified as group I (resistant hypertension) and group II (hypertensive emergency based on the initial presentation or absolute blood pressure). A hypertensive emergency/urgency was defined as persistent BP > 200/100 mmHg or acute target organ damage such as pulmonary edema, cerebrovascular accident / transient ischemic attack, myocardial ischemia/infarction or acute renal failure. A comparison of the biochemical and clinical features in the two groups is shown below.
Using a linear regression model to predict Systolic BP and entering age, gender, serum aldosterone, aldosterone:renin ratio and BMI as predictor variables resulted in no significant predictors. No single biochemical or clinical feature was found to be predictive of a presentation as a hypertensive emergency/urgency and all patients with such a presentation need to be screened for primary aldosteronism. (See Table)
Clinical and Biochemical Features of 2 Presentations of PA
Parameter . | Group 1 . | Group 2 . | P Value . |
---|---|---|---|
Number | 32 | 21 | |
Age, years | 58 ± 13 | 59 ± 16 | .76 |
BMI, kg/m2 | 30 ± 6 | 31 ± 8.4 | .56 |
Gender, F:M | 15:17 | 8:13 | .52 |
Potassium, mEq/L | 3.6 ± 0.63 | 3.7 ± 0.63 | .8 |
Creatinine, mg/dL | 1.0 ± 0.3 | 1.2 ± 0.4 | .11 |
Aldosterone, ng/dL | 22 ± 7 | 26 ± 16 | .3 |
Aldosterone (ng/dL): Plasma Renin Activity (ng/mL/h) | 11–388 | 11–289 | .66 |
Systolic Blood Pressure, mmHg | 172 ± 28 | 208 ± 7 | .001 |
Parameter . | Group 1 . | Group 2 . | P Value . |
---|---|---|---|
Number | 32 | 21 | |
Age, years | 58 ± 13 | 59 ± 16 | .76 |
BMI, kg/m2 | 30 ± 6 | 31 ± 8.4 | .56 |
Gender, F:M | 15:17 | 8:13 | .52 |
Potassium, mEq/L | 3.6 ± 0.63 | 3.7 ± 0.63 | .8 |
Creatinine, mg/dL | 1.0 ± 0.3 | 1.2 ± 0.4 | .11 |
Aldosterone, ng/dL | 22 ± 7 | 26 ± 16 | .3 |
Aldosterone (ng/dL): Plasma Renin Activity (ng/mL/h) | 11–388 | 11–289 | .66 |
Systolic Blood Pressure, mmHg | 172 ± 28 | 208 ± 7 | .001 |
Clinical and Biochemical Features of 2 Presentations of PA
Parameter . | Group 1 . | Group 2 . | P Value . |
---|---|---|---|
Number | 32 | 21 | |
Age, years | 58 ± 13 | 59 ± 16 | .76 |
BMI, kg/m2 | 30 ± 6 | 31 ± 8.4 | .56 |
Gender, F:M | 15:17 | 8:13 | .52 |
Potassium, mEq/L | 3.6 ± 0.63 | 3.7 ± 0.63 | .8 |
Creatinine, mg/dL | 1.0 ± 0.3 | 1.2 ± 0.4 | .11 |
Aldosterone, ng/dL | 22 ± 7 | 26 ± 16 | .3 |
Aldosterone (ng/dL): Plasma Renin Activity (ng/mL/h) | 11–388 | 11–289 | .66 |
Systolic Blood Pressure, mmHg | 172 ± 28 | 208 ± 7 | .001 |
Parameter . | Group 1 . | Group 2 . | P Value . |
---|---|---|---|
Number | 32 | 21 | |
Age, years | 58 ± 13 | 59 ± 16 | .76 |
BMI, kg/m2 | 30 ± 6 | 31 ± 8.4 | .56 |
Gender, F:M | 15:17 | 8:13 | .52 |
Potassium, mEq/L | 3.6 ± 0.63 | 3.7 ± 0.63 | .8 |
Creatinine, mg/dL | 1.0 ± 0.3 | 1.2 ± 0.4 | .11 |
Aldosterone, ng/dL | 22 ± 7 | 26 ± 16 | .3 |
Aldosterone (ng/dL): Plasma Renin Activity (ng/mL/h) | 11–388 | 11–289 | .66 |
Systolic Blood Pressure, mmHg | 172 ± 28 | 208 ± 7 | .001 |